CapsoVision, Inc (CV): R&D Expense
$18.31M
Year ended 2025-12-31
$21.55M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $18.31M | +21.1% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $15.12M | n/a | 2026-03-26, From 2024-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| CapsoVision, Inc (CV) | 2025-12-31 | $18.31M | +21.1% |
| Hyperfine, Inc. (HYPR) | 2025-12-31 | $17.45M | -22.4% |
| Escalon Medical Corp (ESMC) | 2025-06-30 | $753.1K | +9.4% |
| QT Imaging Holdings, Inc. (QTI) | 2025-12-31 | $3.94M | +20.5% |
| Precision Optics Corporation, Inc. (POCI) | 2025-06-30 | $1.16M | +17.9% |
| Nuwellis, Inc. (NUWE) | 2025-12-31 | $2.71M | -15.5% |
| electroCore, Inc. (ECOR) | 2024-12-31 | $2.36M | -55.6% |
| Stereotaxis, Inc. (STXS) | 2025-12-31 | $9.38M | -3.9% |
| Neuraxis, Inc (NRXS) | 2025-12-31 | $493.6K | +13.8% |
Compare CV, HYPR, ESMC, QTI side by side · Screen every company in Electromedical & Electrotherapeutic Apparatus ↗